Med. praxi. 2021;18(4):256-260 | DOI: 10.36290/med.2021.043

Gastroesophageal reflux disease: current state of the issue

MUDr. Eva Mayerová
II. interní klinika FN Plzeň

Gastroesophageal reflux disease is a frequent gastrointestinal disease characterized by a broad spectrum of symptoms, ranging from mild irregular complaints to the presence of serious Barrett's esophagus. In addition to typical symptoms, i.e., pyrosis and regurgitation, there can be a number of atypical and extraesophageal symptoms. Proton pump inhibitors still play a major role in pharmacotherapy. In the past decade, significant advances were made in endoscopic treatment methods which are particularly used in the management of complications. In the majority of cases, the course of the disease is prolonged requiring long-term maintenance treatment. A surgical antireflux procedure is considered when the efficacy of conservative treatment is insufficient.

Keywords: gastroesophageal reflux disease, typical symptoms, extraesophageal symptoms, Barrett's esophagus, proton pump inhibitors, fundoplication.

Published: September 17, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mayerová E. Gastroesophageal reflux disease: current state of the issue. Med. praxi. 2021;18(4):256-260. doi: 10.36290/med.2021.043.
Download citation

References

  1. Bureš J, et al. Refluxní choroba jícnu: standardy České gastroenterologické společnosti - aktualizace 2009.
  2. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastroesophageal reflux disease: systematic review. GUT 2005; 54: 710. Go to original source... Go to PubMed...
  3. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definitiom and classification of gastroesophageal reflux disease: a global evidence - based consensus. Am J. Gastroenterology 2006; 101: 1900. Go to original source... Go to PubMed...
  4. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association. American Gastroenterological Association technical review on the management of Barretś esofagus. Gastroenterology 2011; 140(3): e18-52. Go to original source... Go to PubMed...
  5. Martínek J, Zavoral M. Barrettův jícen - jak sledovat a jak léčit. Postgrad. Med. 2009; 11: 674-682.
  6. Martínek J. Surveillance pacientů s BJ - klíčová role endoskopie. V: Špičák J, Urban O. a kol. Novinky v digestivní endoskopii. Praha: Grada Publishing 2015: 35-41.
  7. Giannini EG, Zentilin P, Dulbecco P, et al. Management strategy for patiens with gastroesophageal reflux disease: a comparison between empiric treatment with esomeprazole and endoscopy oriented treatment. Am J. Gastroenterology 2008; 103: 267. Go to original source... Go to PubMed...
  8. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798. Go to original source... Go to PubMed...
  9. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J. Gastroenterology 2011; 106: 1419. Go to original source... Go to PubMed...
  10. Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastroesophageal reflux disease - like symptoms and endoscopy negative reflux disease. Cochrane Database SystRev 2013; CD002095. Go to original source...
  11. Ip S, Chung M, Moorthy D, et al. Comparative effectiveness of management strategies for gastroesophageal reflux disease: Update. (Prepared by Tufts Medical Center Evidence-based Practice Center under Contract No. HHSA 290-2007-10055-I). Rockville, MD. Agency for Healthcare Research and Quality. September 2011. Available from: http://www.effectivehealthcare.ahrq.gov/ehc/products/165/755/CER29-GERD_20110926.pdf (Accessed on December 19, 2012).
  12. Wolfe MM, Sachs G.Acid suppression:optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118: S9. Go to original source... Go to PubMed...
  13. Hunt R. Acid supression for reflux disease: "off-the-peg" or a tailored approach? Clin. Gastroenterol Hepatol 2012; 10: 210. Go to original source... Go to PubMed...
  14. Lukaš M, Ďuricová D. Terapie inhibitory protonové pumpy v ambulanci internistů a kardiologů. Interní Med. 2010; 12(10): 466-468.
  15. Strand DS, Kim D, Peura DA. "25 Years of Proton Pump Inhibitors: A Comprehensive Review". Gut and Liver. 2017; 11(1): 27-37. Go to original source... Go to PubMed...
  16. DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am. J. Gastroenterology 2005; 100: 190. Go to original source... Go to PubMed...
  17. Komazawa Y, Adachi K, Mihara T, et al. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Hel. pylori infection. J. Gastroenterol Hepatol 2003; 18: 678. Go to original source... Go to PubMed...
  18. Sifrim D, Zerbib F. Diagnosis and management of patiens with reflux symptoms refractory to proton pump inhibitors. Gut 2012; 61: 1340. Go to original source... Go to PubMed...
  19. Fass R. Therapeutic options for refractory gastroesophageal reflux disease. J. Gastroenterol Hepatol 2012; 27(Suppl. 3): 3. Go to original source... Go to PubMed...
  20. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32: 720. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.